<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02237547</url>
  </required_header>
  <id_info>
    <org_study_id>CNEI-2014-TBS-UCMSC-SCI001</org_study_id>
    <nct_id>NCT02237547</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury</brief_title>
  <official_title>Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) and Bone Marrow Mononuclear&#xD;
      Cells (BMMC) from the patient injected into the spinal fluid intrathecally and injected&#xD;
      intravenously (IV) is a safe and therapeutic procedure for spinal cord injury (SCI) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will assess primary safety and secondary efficacy endpoints of autologous&#xD;
      bone marrow mononuclear cells and allogeneic human umbilical cord-derived mesenchymal stem&#xD;
      cells administered to 20 male and female subjects between ages of 18-50 with spinal cord&#xD;
      injury. These cells will be administered intrathecally and intravenously multiple times over&#xD;
      the course of one month.&#xD;
&#xD;
      The primary objective is freedom from treatment-associated adverse events at 3 and 12 months&#xD;
      post-treatment. Secondary objective will be efficacy at baseline, 3 months and 12 months and&#xD;
      will be quantified based on the following: American Spinal Cord Injury Association (ASIA)&#xD;
      classification and the Frankel Scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No enrollment.&#xD;
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>12 weeks, 52 weeks</time_frame>
    <description>12 and 52 weeks after final treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with a change in American Spinal Injury Association (ASIA) score from baseline</measure>
    <time_frame>12 weeks, 52 weeks</time_frame>
    <description>12 and 52 weeks after final treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with a change in Frankel Scale score from baseline</measure>
    <time_frame>12 weeks, 52 weeks</time_frame>
    <description>12 and 52 weeks from final treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>IV and IT UC-MSC and BMMC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells</intervention_name>
    <arm_group_label>IV and IT UC-MSC and BMMC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women between age 18 and 50&#xD;
&#xD;
          -  Paraplegics and quadriplegics with complete or incomplete spinal cord injuries.&#xD;
&#xD;
          -  Willingness to undergo bone marrow derived autologous cell therapy.&#xD;
&#xD;
          -  Ability and willingness to make regular visits to hospital and follow ups during the&#xD;
             protocol procedure and comply with all medical instructions&#xD;
&#xD;
          -  Traumatic Injury of spinal cord with complete or partial damage by Magnetic Resonance&#xD;
             Imaging (MRI) and injury level below C4&#xD;
&#xD;
          -  ASIA impairment scale from A - C&#xD;
&#xD;
          -  Must have proof of health insurance in country of residence.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre- existing or current systemic disease such as lung, liver (exception: history of&#xD;
             uncomplicated hepatitis A), gastrointestinal, cardiac, Human Immunodeficiency Virus&#xD;
             (HIV)&#xD;
&#xD;
          -  History of life threatening allergic- or immune-mediated reaction&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Peripheral muscular dystrophy&#xD;
&#xD;
          -  Lactating or pregnant woman&#xD;
&#xD;
          -  Women capable of childbearing unwilling to use multiple forms of contraception&#xD;
&#xD;
          -  Alcohol drug abuse /dependence&#xD;
&#xD;
          -  Positive test result for hepatitis A and Hepatitis B OR C&#xD;
&#xD;
          -  Major-traumatic brain injury and psychiatric illness&#xD;
&#xD;
          -  Open injuries&#xD;
&#xD;
          -  Active infectious diseases&#xD;
&#xD;
          -  Life expectancy of less than one year due to terminal condition&#xD;
&#xD;
          -  Neurodegenerative diseases&#xD;
&#xD;
          -  Primary hematologic diseases&#xD;
&#xD;
          -  Any of the following medications that cannot be discontinued one week prior to the&#xD;
             first stem cell administration and throughout the course of treatment. (1 week before&#xD;
             visit 2 through one week after visit 12)&#xD;
&#xD;
               -  Antibiotics&#xD;
&#xD;
               -  Antifungals&#xD;
&#xD;
               -  Antivirals&#xD;
&#xD;
               -  Blood thinners (to avoid bleeding risk during bone marrow aspiration and IT&#xD;
                  procedures)&#xD;
&#xD;
               -  High doses of Vitamin D or fish oils (since these might prolong bleeding times)&#xD;
&#xD;
          -  Bone reflecting increased risk for spinal puncture&#xD;
&#xD;
          -  Hepatic dysfunction&#xD;
&#xD;
          -  Other medical complications that contraindicate surgery, including major respiratory&#xD;
             complications&#xD;
&#xD;
          -  Participation in another clinical trial&#xD;
&#xD;
          -  Coagulopathies&#xD;
&#xD;
          -  Uncorrected coagulopathy during the baseline period defined as: International&#xD;
             Normalized Ratio (INR) &gt; 1.4; Partial Thromboplastin Time (PTT) &gt; 35 sec; Platelet&#xD;
             Count (PLT) &lt; 100,000.&#xD;
&#xD;
          -  Pre-injury history of seizure disorder and/or neurological impairment where&#xD;
             participation in age-appropriate pain rating scales would not be practical or possible&#xD;
&#xD;
          -  Subject does not sign informed consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelson Novarro, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Stem Cell Institute</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>September 9, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2014</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord injury</keyword>
  <keyword>mesenchymal</keyword>
  <keyword>bone marrow</keyword>
  <keyword>mononuclear cells</keyword>
  <keyword>stem cells</keyword>
  <keyword>umbilical cord</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

